Information  X 
Enter a valid email address

Synairgen PLC Ord 1P (SNG)

Related News

26-May-2020 07:10 AM

Synairgen posts annual loss; analysing potential Covid-19 treatment

Respiratory drug developer Synairgen posted a full-year loss, as it continued to spend on R&D, and said an investigation into a potential Covid-19 treatment was progressing well. Pre-tax losses for the year through December amounted to £4.8m, compa
25-Feb-2019 04:37 PM

Synairgen swings to loss on higher R&D spend

Respiratory drug developer Synairgen swung to an annual loss as it ramped up R&D spending. Pre-tax losses for the year through December amounted to £4.1m, compared to profits of £1.6m on-year. '2018 was a year of excellent operational p
25-Sep-2018 01:07 PM

Synairgen losses deepen on higher R&D spend

Respiratory drug company Synairgen posted a deeper first-half loss as it ramped up spending trialling a treatment for chronic obstructive pulmonary disease. Pre-tax losses for the six months through June amounted to £1.85m, widening from a loss of
22-Jun-2018 08:30 AM

Broker Forecast - finnCap issues a broker note on Synairgen PLC

finnCap today reaffirms its corporate investment rating on Synairgen PLC (LON:SNG) and raised its price target to 63p (from 35p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
15-Mar-2018 09:21 AM

Synairgen swings to profit

Synairgen, the respiratory drug discovery and development company, swung to a profit from operations of £1.62 million in 2017, from a loss of £3.44 million the year before. Revenues for the year were £5.03 million (2016: £nil). R
07-Feb-2018 09:34 AM

Synairgen commences trail of obstructive pulmonary disease treatment

Synairgen said first patients had been dosed in a Phase II trial of an inhaled treatment for patients with chronic obstructive pulmonary disease. The first part of the trial of the treatment, referred to as SNG001, was scheduled to complete in the first
07-Feb-2018 08:20 AM

Broker Forecast - finnCap issues a broker note on Synairgen PLC

finnCap today reaffirms its corporate investment rating on Synairgen PLC (LON:SNG) and set its price target at 35p. Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk...
14-Dec-2017 09:59 AM

Synairgen revises collaboration with Pharmaxis

Synairgen, the respiratory drug discovery and development company, has revised its collaboration agreement with Pharmaxis following the completion of preclinical studies and the commencement of the Phase I clinical trial with its LOXL2 inhibitor programme
28-Jun-2017 01:01 PM

Synairgen shareholders pass all resolutions at AGM

Synairgen has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:01pm: (LON:SNG) Synairgen PLC share price was 0p at 8.75p Story provided by StockMarketWire.com...
16-Sep-2015 07:39 AM

Synairgen swings to H1 pretax loss

Synairgen has swung to an H1 pretax loss of £1.0m, from a prior same period profit of £1.9m. Revenue was £25,000, from £4.25m. CEO Richard Marsden commented: "During the period, Synairgen has been focused on working with AstraZeneca to support
21-Aug-2015 01:33 PM

Synairgen schedules interims

Synairgen will issue its interim results for the six month period to the end of June on 16 September. At 1:33pm: (LON:SNG) Synairgen PLC share price was 0p at 35.5p Story provided by StockMarketWire.com...
05-Aug-2015 07:33 AM

Synairgen announces research collaboration

Synairgen and Australian pharmaceutical company Pharmaxis Ltd have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). IPF
03-Mar-2015 09:21 AM

Synairgen swings to FY pretax profit

Synairgen has swung to a FY pretax profit of £1.13m, from a loss of £2.27m. Revenue was £4.3m, from nil. Chairman Simon Shaw said: "We are delighted with the progress Synairgen has made during what has been a transformational year with the lice
20-Mar-2014 08:15 AM

Synairgen FY pretax loss narrows slightly

Synairgen posted a FY pretax loss of £2.3m, from £2.5m a year earlier. Revenue was nil. Most of the loss was research and development expenditure, and other administrative expenses. Chairman Simon Shaw said Synairgen made significant progress this year
12-Aug-2013 07:36 AM

Synairgen narrows H1 pretax loss to £1.2m

Synairgen narrowed its first-half pretax loss to £1.19 million, from a loss of £1.26 million. It booked nil revenue. Total administrative expenses was £1.20 million, from £1.28 million. Chairman Simon Shaw said: "Significant progress has been
10-Jun-2013 01:54 PM

Synairgen resolutions passed at AGM

Synairgen has confirmed that all resolutions proposed at its annual general meeting held earlier today (10 June) were duly passed. At 1:54pm: (LON:SNG) Synairgen share price was 0p at 40p Story provided by StockMarketWire.com...
09-May-2013 01:09 PM

Synairgen schedules AGM

Synairgen - the respiratory drug discovery and development company - will hold its annual general meeting at the offices of Fasken Martineau, 17 Hanover Square, London W1S 1HU, on 10 June at noon. At 1:09pm: (LON:SNG) Synairgen share price was -2.25p a
13-Feb-2013 07:39 AM

Synairgen FY pretax loss £2.5m

Synairgen said in a trading update that its pretax loss for the six months to end-December 2012 was £2.5 million, from £2.2 million in the year-earlier same period. "In 2012 our interferon beta programme achieved a significant milestone, generatin
05-Dec-2012 07:57 AM

Synairgen in disucssions with potential licensing partners

Synairgen announced its interim results for the six months ended 30 June 2012. Since the interim period-end, the Company has made significant progress and has progressed discussions with potential licensing partners for SNG001 (inhaled interferon beta) fo
31-Aug-2012 07:55 AM

Synairgen presents proof of concept study

Synairgen has confirmed that Professor Ratko Djukanovic, Chief Investigator on Synairgen's recent Phase II study of inhaled interferon beta, will present "The effects of interferon beta on cold-induced asthma exacerbations" during the sessi
10-Aug-2012 09:48 AM

Synairgen has funds for future development

Synairgen (LSE: SNG), the respiratory drug company with a particular focus on viral defence of the lungs, reduced its losses in the six months ended 30 June 2012. It has revealed successful initial results from the Phase II proof of concept trial of inha
01-Feb-2012 09:33 AM

Synairgen hopes for positive data from Phase II asthma trial

The board of Synairgen says the positive data from the Phase II asthma trial in March 2012 will be a pivotal requirement for it to pursue the further development of inhaled IFN-beta with a licensing partner. Commenting, Simon Shaw, Chairman of Synairgen
25-Nov-2011 08:53 AM

Positive results in viral pneumonia study for Synairgen

Synairgen, the respiratory drug discovery and development company has announced positive data from its pre-clinical study evaluating the effectiveness of aerosolised interferon beta ('IFN-beta') against viral pneumonia. Richard Marsden, CEO
13-Sep-2011 09:27 AM

Loss-making Synairgen positive over current trials

Synairgen plc, the respiratory drug discovery and development company, has announced its audited results for the year ended 30 June 2011 showing fundraising of £2.5 million (net of expenses) completed in June 2011 to provide additional finance for the com
28-Jun-2011 08:53 AM

Synairgen positive on asthma study latest

Synairgen plc, the respiratory drug discovery and development company with a particular focus on viral defence of the lungs, has provided an update on its Phase II asthma study. The company has announced that the outcome of the review does not require i
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t